Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - October 2013


European Pharmaceutical Pricing & Reimbursement

21 Oct 2013 - 22 Oct 2013 - London, UK



Bookmark and Share


We are delighted to announce SMi's European Pharmaceutical Pricing & Reimbursement. Now in its 19th year, this event has been one of the oldest market leaders in the pharmaceutical industries calendar for some time.

The agenda aims to bring together experts from key industry personnel from big Pharma, biotech and academia who will thoroughly explain and offer advice on P&R and market access. The conference will focus on European and US markets including country specific case studies proving strategic insight into how a wide range of complex issues can be readily adapted to.

This conference provides the most comprehensive up to date centre of information with reimbursement evidence inproduct development; Impact of HTA in different markets and international based price referencing.

KEY REASONS TO ATTEND

Understand how value based pricing will affect the U.Ks pricing market and what to expect

Discuss key market access strategies with a range of case studies including those currently being developed successfully with orphan drugs

Evaluate current strategies with the new NICE network reforms

See the establishment of the pan-European HTA network and its current effects

Develop future cross sector market access strategies


Register online here: www.smi-online.co.uk/2013europricing26.asp

Alternatively, contact: Jonathan Collins on +44 (0)20 7827 6734 or email: jcollins@smi-online.co.uk 

Academic & Group discounts available



Further information
Scientific News
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!